# Phase 2 Lung Diseases trials recruiting: 48 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 48 trials in phase 2 for Lung Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lung Diseases trials: 48 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lung-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 48
- Recruiting or not yet: 48
- Read on: November 19, 2026

## Trials

The 25 newest of 48, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923591 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923591) |
| November 4, 2026 | NCT07915791 | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe... | GlaxoSmithKline | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915791) |
| October 26, 2026 | NCT07896252 | Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients | AeroRx Therapeutics Inc. | Phase 2 | Recruiting | COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896252) |
| September 15, 2026 | NCT07821398 | Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821398) |
| August 12, 2026 | NCT07759245 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Eli Lilly and Company | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759245) |
| July 30, 2026 | NCT07737249 | Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Interstitial Lung Diseases | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737249) |
| May 7, 2026 | NCT07572383 | Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Interstitial Lung Disease, Pulmonary Fibrosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572383) |
| April 13, 2026 | NCT07525375 | A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in... | AstraZeneca | Phase 2 | Recruiting | Asthma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525375) |
| March 23, 2026 | NCT07489066 | Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC | Pfizer | Phase 2 | Recruiting | Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489066) |
| March 23, 2026 | NCT07486869 | Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | University of Miami | Phase 2 | Recruiting | Dermatomyositis, Dermatomyositis Sine Myositis, Dermatomyositis With Myopathy, Dermatomyositis With Respiratory... | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486869) |
| March 16, 2026 | NCT07473700 | Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease | Tectonic Operating Company, Inc. | Phase 2 | Recruiting | Hypertension, Pulmonary, Lung Diseases, Interstitial | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473700) |
| March 2, 2026 | NCT07443436 | Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Interstitial Lung Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443436) |
| February 19, 2026 | NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420439) |
| February 9, 2026 | NCT07398287 | Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease | Region Skane | Phase 2 | Recruiting | Interstitial Lung Disease (ILD) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398287) |
| January 12, 2026 | NCT07333183 | A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmovant, Inc. | Phase 2 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333183) |
| January 7, 2026 | NCT07323732 | A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | NSCLC, NSCLC, Stage I, NSCLC Stage II, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07323732) |
| December 16, 2025 | NCT07284459 | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284459) |
| September 16, 2025 | NCT07175038 | A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung... | AllRock Bio, Inc. | Phase 2 | Recruiting | Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175038) |
| August 13, 2025 | NCT07120503 | Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Asthma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07120503) |
| July 10, 2025 | NCT07059091 | Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Johns Hopkins University | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD), Allergies | 334 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059091) |
| July 2, 2025 | NCT07047690 | A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis | Galderma R&D | Phase 2 | Recruiting | Systemic Sclerosis | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047690) |
| May 18, 2025 | NCT06977581 | A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Pfizer | Phase 2 | Recruiting | Asthma | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06977581) |
| May 13, 2025 | NCT06968845 | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Rein Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06968845) |
| April 8, 2025 | NCT06917573 | PALACE: Cemiplimab Trial According to ctDNA Levels | Fundación GECP | Phase 2 | Recruiting | Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell... | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06917573) |
| January 6, 2025 | NCT06758700 | Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758700) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| Pulmovant, Inc. | 1 |
| AllRock Bio, Inc. | 1 |
| Yale University | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| University of Alberta | 1 |
| Scleroderma Research Foundation, Inc. | 1 |
| Johns Hopkins University | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |
| Massachusetts General Hospital | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| [United Therapeutics](https://specstream.ai/data/clinical-trials/company/united-therapeutics) | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| IRulya Therapeutics Inc. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| AeroRx Therapeutics Inc. | 1 |
| Contineum Therapeutics | 1 |
| National Institute of Environmental Health Sciences (NIEHS) | 1 |
| Fundación GECP | 1 |
| Peking Union Medical College Hospital | 1 |
| Dana-Farber Cancer Institute | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| aTyr Pharma, Inc. | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 33 |
| France | 9 |
| Spain | 9 |
| United Kingdom | 9 |
| Canada | 8 |
| Germany | 8 |
| Poland | 8 |
| Australia | 7 |
| South Korea | 6 |
| Italy | 5 |
| Argentina | 5 |
| China | 5 |
| Czechia | 3 |
| Hungary | 3 |
| Mexico | 3 |
| Serbia | 3 |
| Japan | 3 |
| Taiwan | 3 |
| Denmark | 3 |
| Bulgaria | 3 |
| Romania | 3 |
| Hong Kong | 2 |
| Israel | 2 |
| Puerto Rico | 2 |
| Belgium | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [T-shirt printers in the United States](https://specstream.ai/data/businesses/t-shirt-printers/united-states)
- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
- [Architecture firms in the United States](https://specstream.ai/data/businesses/architecture-firms/united-states)
- [Mongolian restaurants in the United States](https://specstream.ai/data/businesses/mongolian-restaurants/united-states)
- [Child care centers in the United States](https://specstream.ai/data/businesses/child-care-centers/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
